Long‐term and concentration‐dependent beneficial effect of efavirenz on HDL‐cholesterol in HIV‐infected patients

Aims To investigate the long‐term effects of efavirenz on cholesterol (TC), high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein (LDL‐C) and triglycerides (TG). Methods Thirty‐four HIV‐infected patients who commenced efavirenz therapy were monitored for 36 months. Results In patient...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2006-05, Vol.61 (5), p.601-604
Main Authors: Pereira, Sofia A., Branco, Teresa, Côrte‐Real, Rita M., Germano, Isabel, Lampreia, Fátima, Caixas, Umbelina, Monteiro, Emília C.
Format: Article
Language:English
Subjects:
Adult
Benzoxazines
Biological and medical sciences
cardiovascular risk
Cholesterol - blood
Cholesterol, HDL - blood
Dose-Response Relationship, Drug
efavirenz
Female
Follow-Up Studies
Glycoproteins - blood
HDL‐cholesterol
HIV infection
HIV Infections - blood
HIV Infections - drug therapy
HIV-1
Human immunodeficiency virus
Human viral diseases
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
Immunopathology
Infectious diseases
Male
Medical sciences
Oxazines - therapeutic use
Pharmacology. Drug treatments
plasma concentrations
Prospective Studies
Reverse Transcriptase Inhibitors - therapeutic use
Short Reports
Time Factors
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims To investigate the long‐term effects of efavirenz on cholesterol (TC), high‐density lipoprotein cholesterol (HDL‐C), low‐density lipoprotein (LDL‐C) and triglycerides (TG). Methods Thirty‐four HIV‐infected patients who commenced efavirenz therapy were monitored for 36 months. Results In patients with baseline HDL‐C
ISSN:0306-5251
1365-2125
DOI:10.1111/j.1365-2125.2006.02619.x